Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma

Summary

Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells in patients with uremia-associated urothelial carcinoma. Secondary Objective: To evaluate the general safety and tolerability of oral lycopene 30 mg per day for 12 weeks in uremic patients.

Timeline

Start

2006-01

Primary completion

—

Completion

—

Outcome

Outcome not reported

Stopped (Business): “This study was for National Science Council project. The study was not funded, so the study was withdrawn.”

Drugs

Indications